Clinical Trial to Evaluate the Safety and Immunogenicity of a Trivalent Surface Antigen Seasonal Influenza Vaccine Produced in Mammalian Cell Culture and Administered to Young and Elderly Adults with and without A(H1N1) Pre-Vaccination

Immunogenicity, Safety and Reactogenicity of a Mammalian Cell-Culture–Derived Influenza Vaccine in Healthy Children and Adolescents Three to Seventeen Years of Age

(2012) Timo Vesikari et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Safety assessment and immunogenicity of a cell-culture-derived influenza vaccine in adults and elderly subjects over three successive influenza seasons

(2012) Agnieszka Szymczakiewicz-Multanowska et al.   Human Vaccines & Immunotherapeutics

Validation of the safety of MDCK cells as a substrate for the production of a cell-derived influenza vaccine

(2010) David Onions et al.   BIOLOGICALS

Seroprevalence Following the Second Wave of Pandemic 2009 H1N1 Influenza in Pittsburgh, PA, USA

(2010) Shanta M. Zimmer et al.   PLoS One

Safety and immunogenicity of a trivalent single dose seasonal influenza vaccine containing pandemic A(H1N1) antigen in younger and elderly subjects: A phase III open-label single-arm study

(2010) M. Loebermann et al.   VACCINE

Trivalent MDCK cell culture-derived influenza vaccine Optaflu®(Novartis Vaccines)

(2009) Alexander Doroshenko et al.   Expert Review of Vaccines

Randomized, Double‐Blind Controlled Phase 3 Trial Comparing the Immunogenicity of High‐Dose and Standard‐Dose Influenza Vaccine in Adults 65 Years of Age and Older

(2009) Ann R. Falsey et al.   JOURNAL OF INFECTIOUS DISEASES

Epidemiological, antigenic and genetic characteristics of seasonal influenza A(H1N1), A(H3N2) and B influenza viruses: Basis for the WHO recommendation on the composition of influenza vaccines for use in the 2009–2010 Northern Hemisphere season

(2009) Ian G. Barr et al.   VACCINE

A quantitative risk assessment of exposure to adventitious agents in a cell culture-derived subunit influenza vaccine

(2008) Jens-Peter Gregersen   VACCINE